Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493464 | 0.93 | APLNR (0.42) | APLNROPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL29904041 | 0.93 | APLNR (0.41) | APLNROPRM1OPRD1NTSR1NMUR2 | |
| SCHEMBL29800494 | 0.89 | OPRM1 (0.44) | APLNROPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL29641591 | 0.89 | KEAP1 (0.49) | PTPN1 | |
| SCHEMBL29800885 | 0.87 | NAA50 (0.47) | APLNROPRM1OPRD1NTSR1NMUR2 | |
| SCHEMBL29569246 | 0.86 | NTSR1 (0.44) | APLNROPRD1NTSR1PTPN1F2 | |
| SCHEMBL29800900 | 0.86 | NTSR1 (0.48) | OPRD1NTSR1PTPN1F2 | |
| SCHEMBL29493717 | 0.84 | NTSR2 (0.42) | APLNROPRM1OPRD1NTSR1F2 | |
| SCHEMBL4726312 | 0.84 | APLNR (0.40) | APLNROPRM1OPRD1PTPN1GRB2 | |
| SCHEMBL4726314 | 0.84 | APLNR (0.40) | APLNROPRM1OPRD1PTPN1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20240108781-A1 | POLYMERIC TREATMENT COMPOSITIONS | MICROVENTION, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11801326-B2 | Polymeric treatment compositions | MICROVENTION, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220273825-A1 | RADIOPAQUE PARTICLE COMPOSITIONS AND USES THEREOF | GUSTAVE ROUSSY TRANSFERT (FR) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | PDGFRB, ERBB2, AKT1 | APLNR 1990/4885OPRM1 1480/4885OPRD1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.